Douglas B. Johnson, MD, MSCI, assistant professor of medicine, Vanderbilt University Medical Center, clinical director, Melanoma Research Program, Vanderbilt-Ingram Cancer Center, discusses the need to identify novel biomarkers in melanoma.
Video Reports
Dr. Hamid on TMB as a Biomarker for Immunotherapy Response in Melanoma
TMB is not just for melanoma, says Hamid. By examining TMB, investigators have done a significant job in helping to understand which patients will respond best to immunotherapy across a multitude of tumor types.
Impressive Results’ From Stage III Melanoma Studies: ASCO 2020
COMBI-AD is an adjuvant trial in resected stage IIIA, IIIB, and IIIC melanoma (per the American Joint Committee on Cancer [AJCC] 7th edition criteria) in patients who had completion lymphadenectomies. The study was a large randomized, blinded phase 3 study of 870 patients where there was an excellent balance between dabrafenib/trametinib for 1 year vs placebo.
Dr. Long on the Rationale for the Phase 3 COMBI-i Trial in BRAF V600¬–Mutant Melanoma
Georgina Long, BSc, PhD, MBBS, FRACP, co-medical director, Melanoma Institute Australia (MIA), chair of Melanoma Medical Oncology and Translational Research, MIA and Royal North Shore Hospital, University of Sydney, discusses the rationale for the phase 3 COMBI-i trial in BRAF V600–mutant melanoma.